NYVEPRIA

Manufacturer:

Pfizer

Name:

NYVEPRIA

HCPCS Code Descriptor:

Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg

Category:

Q Code

HCPCS:

Q5122

NDC(s):

00069-0324-01

Primary Type:

Oncology Biosimilar Colony Stimulating Factor

Generic Status:

Single-Source

Route of Administration:

Subcutaneous

About:

NYVEPRIA is an Oncology Biosimilar Colony Stimulating Factor drug manufactured by Pfizer and administered via the Subcutaneous route of administration. The Q Code: Q5122 is aligned to the drug NYVEPRIA.

Nyvepria (pegfilgrastim) is a man-made protein that aids in the production of certain white blood cells (neutrophils). This medication can be used as a preventative measure to ensure that a patient doesn’t have a deficiency of neutrophils. Nyvepria is produced by Pfizer and is a biosimilar to the medication Neulasta (J2506). Nyvepria has been aligned to the HCPCS code Q5122 since January 2021.